Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKainos Group Regulatory News (KNOS)

Share Price Information for Kainos Group (KNOS)

Share Price is delayed by 15 minutes
Get Live Data
849.50    -28.50 (-3.25%)
Bid:
852.50
Ask:
854.50
Spread: 2.00 (0.235%)
Market Cap: £978.40m
KNOS Live PriceLast checked at - London Stock Exchange

Intraday Kainos Group Share Chart

Kainos Acquires Formulate and Implexa

11 Nov 2019 07:01

RNS Number : 8720S
Kainos Group plc
11 November 2019
 

RNS REACH

11 November 2019

Kainos Group plc

 

("Kainos" or the "Company")

 

Kainos Acquires Formulate and Implexa

 

Kainos (LSE: KNOS), a leading UK-based provider of digital services and platforms, is pleased to announce today further investment into Adaptive Insights' UK and European markets through the acquisitions of Formulate (Adaptive) Limited ("Formulate"), and the Adaptive Insights arm of Implexa GmbH ("Implexa").

 

Formulate is a leading UK and European partner to Adaptive Insights: a financial and business planning software business which is part of Workday, Inc. Established in 2016 and headquartered in Worcestershire in the UK, Formulate is one of the leading European partners to Adaptive Insights. Formulate supports customers in implementing Adaptive Insight's software; building and refining forecasting solutions. Formulate's team of 16 combines both software and consulting capabilities, and provides its services to more than 100 customers across the UK and Europe.

 

Implexa is the only accredited Adaptive Insights partner in Germany, and adds Hamburg-based software and consulting capabilities to Kainos' existing Frankfurt presence and capabilities.

 

Both acquisitions help Kainos to build and expand on its Workday offering, and to grow its presence in key markets. By acquiring both businesses, Kainos strengthens its capabilities to sell, deliver and support Adaptive Insights financial planning customer success across the UK and wider Europe.

 

The terms of the investments have not been disclosed.

 

Commenting on the acquisition Brendan Mooney, CEO, Kainos, said:

 

"I am delighted to welcome the Formulate and Implexa teams to Kainos. The quality and unique expertise of the teams, paired with their complementary values, were integral in our decision to make these acquisitions.

 

We continue to see growing demand from organisations across the UK and Europe in modernising employee experience and financial management systems. By partnering with Workday, and as it continues to expand its products, we'll be able to enhance our value to customers."

 

For further information, please contact:

 

Kainos Group plc via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Richard McCann, Chief Financial Officer

 

Investec Bank plc +44 20 7597 5970

Patrick Robb / Sebastian Lawrence

 

Canaccord Genuity +44 20 7523 4606

Simon Bridges

 

FTI Consulting LLP +44 20 3727 1000

Matt Dixon / Kwaku Aning / Leah Dudley

 

 

About Kainos

Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms.

 

The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. ('Workday'), responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers.

 

The Group's Digital Platforms comprise specialised digital platforms in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.

 

Kainos has over 1,550 people across 12 offices in Europe and North America.

 

Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com 

 

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFSLFWAFUSEFF
Date   Source Headline
4th Jun 202611:31 amRNSDirector / PDMR shareholdings
1st Jun 202610:27 amRNSTotal Voting Rights
18th May 20267:00 amRNSFull Year Results
18th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 202611:06 amRNSTotal Voting Rights
28th Apr 20261:38 pmRNSBoard and Board Committee Changes
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSYear-end Trading Update
14th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 202610:22 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20265:10 pmRNSDirector Declaration
24th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20263:16 pmRNSNotification of Major Holdings
17th Mar 202611:28 amRNSDirector/PDMR shareholdings
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20264:58 pmRNSNotification of Transactions of Director/PDMR
12th Mar 20262:13 pmRNSHolding(s) in Company
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20269:30 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20269:43 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.